Nilotinib:from animal-based studies to clinical investigation in Alzheimer's disease patients  

作　　者：Annalisa Nobili Marcello D’Amelio Maria Teresa Viscomi 

机构地区：[1]Department of Medicine and Surgery,University Campus Bio-Medico,Department of Experimental Neuroscience,IRCCS Santa Lucia Foundation,Rome,Italy [2]Department of Life Science and Public Health Section of Histology and Embryology,UniversitàCattolica del Sacro Cuore,Fondazione Policlinico Universitario“A.Gemelli”,IRCCS,Rome,Italy

出　　处：《Neural Regeneration Research》2023年第4期803-804,共2页中国神经再生研究（英文版）

基　　金：supported by Linea D.1.2021 UniversitàCattolica del S.Cuore(to MTV);by the Italian Ministry of Health(IT)[Research Grant:RF-2018-12365527,to MDA and MTV];supported by the American Alzheimer’s Association[AARG-21-851219];by Fondazione Roma(Rome,Italy)。

摘　　要：Since their first description in the brains of patients suffering from Alzheimer ’s disease(AD), more than 100 years ago, extracellular amyloid-β(Aβ) plaques and intracellular neurofibrillary tangles have been the principal focus of AD research. However, this focus has led to the failure of several long and promising clinical trials, and the efficacy of new Aβ-targeting drugs to slow down the disease progression is still controversial despite being successful in reducing the Aβ load.

关 键 词：ALZHEIMER AΒ DRUGS 

分 类 号：R749.16[医药卫生—神经病学与精神病学]